JP2016522232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522232A5 JP2016522232A5 JP2016520443A JP2016520443A JP2016522232A5 JP 2016522232 A5 JP2016522232 A5 JP 2016522232A5 JP 2016520443 A JP2016520443 A JP 2016520443A JP 2016520443 A JP2016520443 A JP 2016520443A JP 2016522232 A5 JP2016522232 A5 JP 2016522232A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- alkyl
- pyrimidin
- alkylene
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 31
- 239000001257 hydrogen Substances 0.000 claims 31
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000002431 hydrogen Chemical group 0.000 claims 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 150000001204 N-oxides Chemical class 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- -1 1,2,4-triazin-3-yl Chemical group 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 claims 3
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 3
- 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000004317 1,3,5-triazin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=N1 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 claims 2
- ZRWZXFWLXHVIPU-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]-5-methoxypyrazol-3-yl]-5-methoxy-n-pyrimidin-4-ylpyrimidin-4-amine Chemical compound COC1=CC(C=2N=C(NC=3N=CN=CC=3)C(OC)=CN=2)=NN1CC1=CC=CC=C1F ZRWZXFWLXHVIPU-UHFFFAOYSA-N 0.000 claims 1
- HYDXNARVPWUUOI-UHFFFAOYSA-N 2-[1-[(4-ethoxy-2,6-difluorophenyl)methyl]-4-methylpyrazol-3-yl]-5-methoxy-n-pyrimidin-4-ylpyrimidin-4-amine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1N=C(C=2N=C(NC=3N=CN=CC=3)C(OC)=CN=2)C(C)=C1 HYDXNARVPWUUOI-UHFFFAOYSA-N 0.000 claims 1
- UHPLKNDBSSWLRM-UHFFFAOYSA-N 2-[4-chloro-1-[(4-ethoxy-2,6-difluorophenyl)methyl]pyrazol-3-yl]-5-methoxy-n-pyrimidin-4-ylpyrimidin-4-amine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1N=C(C=2N=C(NC=3N=CN=CC=3)C(OC)=CN=2)C(Cl)=C1 UHPLKNDBSSWLRM-UHFFFAOYSA-N 0.000 claims 1
- OPPDGMAYJWMPQZ-UHFFFAOYSA-N 2-[4-chloro-5-cyclopropyl-1-[(4-ethoxy-2,6-difluorophenyl)methyl]pyrazol-3-yl]-n-pyrimidin-4-ylpyrimidin-4-amine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C(C2CC2)=C(Cl)C(C=2N=C(NC=3N=CN=CC=3)C=CN=2)=N1 OPPDGMAYJWMPQZ-UHFFFAOYSA-N 0.000 claims 1
- OLWZHWUCXLHNRU-UHFFFAOYSA-N 2-[5-cyclopropyl-1-[(4-ethoxy-2,6-difluorophenyl)methyl]-4-methylpyrazol-3-yl]-5-methoxy-n-pyridazin-4-ylpyrimidin-4-amine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C(C2CC2)=C(C)C(C=2N=C(NC=3C=NN=CC=3)C(OC)=CN=2)=N1 OLWZHWUCXLHNRU-UHFFFAOYSA-N 0.000 claims 1
- WWQQBGVPQYCREG-UHFFFAOYSA-N 2-[5-cyclopropyl-1-[(4-ethoxy-2,6-difluorophenyl)methyl]-4-methylpyrazol-3-yl]-5-methoxy-n-pyrimidin-4-ylpyrimidin-4-amine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C(C2CC2)=C(C)C(C=2N=C(NC=3N=CN=CC=3)C(OC)=CN=2)=N1 WWQQBGVPQYCREG-UHFFFAOYSA-N 0.000 claims 1
- WFQPHSHXIIXQOY-UHFFFAOYSA-N 2-[5-cyclopropyl-1-[(4-ethoxy-2,6-difluorophenyl)methyl]-4-methylpyrazol-3-yl]-n-pyrimidin-4-ylpyrimidin-4-amine Chemical compound FC1=CC(OCC)=CC(F)=C1CN1C(C2CC2)=C(C)C(C=2N=C(NC=3N=CN=CC=3)C=CN=2)=N1 WFQPHSHXIIXQOY-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13173280.2 | 2013-06-21 | ||
| EP13173280 | 2013-06-21 | ||
| PCT/EP2014/062694 WO2014202588A1 (en) | 2013-06-21 | 2014-06-17 | Heteroaryl substituted pyrazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016522232A JP2016522232A (ja) | 2016-07-28 |
| JP2016522232A5 true JP2016522232A5 (enExample) | 2017-07-20 |
Family
ID=48651937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520443A Pending JP2016522232A (ja) | 2013-06-21 | 2014-06-17 | ヘテロアリール置換されたピラゾール類 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160168130A1 (enExample) |
| EP (1) | EP3010911A1 (enExample) |
| JP (1) | JP2016522232A (enExample) |
| CN (1) | CN105452242A (enExample) |
| CA (1) | CA2916109A1 (enExample) |
| HK (1) | HK1223097A1 (enExample) |
| WO (1) | WO2014202588A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| EP2794596B1 (en) | 2011-12-21 | 2017-05-31 | Bayer Intellectual Property GmbH | Substituted benzylpyrazoles |
| WO2014147204A1 (en) * | 2013-03-21 | 2014-09-25 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| WO2014202583A1 (en) * | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| CA2916194A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| CN105408324A (zh) | 2013-06-21 | 2016-03-16 | 拜耳制药股份公司 | 取代的苄基吡唑 |
| US9682974B2 (en) | 2013-10-30 | 2017-06-20 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| EP3092231B1 (en) * | 2013-12-11 | 2018-06-27 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
| JP6545199B2 (ja) | 2014-06-17 | 2019-07-17 | バイエル ファーマ アクチエンゲゼルシャフト | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 |
| WO2016042084A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 inhibitors |
| SG11201705908VA (en) | 2015-01-28 | 2017-08-30 | Bayer Pharma AG | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CN107922389A (zh) | 2015-06-17 | 2018-04-17 | 拜耳制药股份公司 | 3‑氨基‑1,5,6,7‑四氢‑4h‑吲哚‑4‑酮 |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| TW202227405A (zh) * | 2020-08-24 | 2022-07-16 | 以色列商安道麥馬克西姆有限公司 | 用於製備經取代的吡唑之方法 |
| EP4217070A1 (en) | 2020-09-23 | 2023-08-02 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
| WO2022072634A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| KR20230107419A (ko) | 2020-10-09 | 2023-07-14 | 스코르피온 테라퓨틱스, 인코퍼레이티드 | 암 치료 방법 |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| WO2024254266A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| WO2024254298A1 (en) | 2023-06-08 | 2024-12-12 | Scorpion Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7863282B2 (en) * | 2003-03-14 | 2011-01-04 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| MX377600B (es) * | 2010-06-30 | 2025-03-10 | Cyclerion Therapeutics Inc | Estimuladores de sgc. |
| EP2702055A1 (en) * | 2011-04-11 | 2014-03-05 | Nerviano Medical Sciences S.r.l. | Pyrazolyl-pyrimidine derivatives as kinase inhibitors |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| EP2794596B1 (en) * | 2011-12-21 | 2017-05-31 | Bayer Intellectual Property GmbH | Substituted benzylpyrazoles |
| CA2916194A1 (en) * | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
-
2014
- 2014-06-17 US US14/899,418 patent/US20160168130A1/en not_active Abandoned
- 2014-06-17 WO PCT/EP2014/062694 patent/WO2014202588A1/en not_active Ceased
- 2014-06-17 JP JP2016520443A patent/JP2016522232A/ja active Pending
- 2014-06-17 CN CN201480043727.6A patent/CN105452242A/zh active Pending
- 2014-06-17 EP EP14730908.2A patent/EP3010911A1/en not_active Withdrawn
- 2014-06-17 CA CA2916109A patent/CA2916109A1/en not_active Abandoned
- 2014-06-17 HK HK16111251.3A patent/HK1223097A1/zh unknown